A Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Phase Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of SYHA1805 in Chinese Healthy Adult Subjects.
Latest Information Update: 05 Jun 2023
At a glance
- Drugs SYHA-1805 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 02 Aug 2021 New trial record